This company listing is no longer active
Destiny Pharma Beheer
Beheer criteriumcontroles 3/4
Destiny Pharma's CEO is Chris Tovey, appointed in Sep 2023, has a tenure of less than a year. total yearly compensation is £123.00K, comprised of 89.4% salary and 10.6% bonuses, including company stock and options. directly owns 0.042% of the company’s shares, worth £1.90K. The average tenure of the management team and the board of directors is 3.4 years and 6.3 years respectively.
Belangrijke informatie
Chris Tovey
Algemeen directeur
UK£123.0k
Totale compensatie
| Percentage CEO-salaris | 89.4% |
| Dienstverband CEO | less than a year |
| Eigendom CEO | 0.04% |
| Management gemiddelde ambtstermijn | 3.4yrs |
| Gemiddelde ambtstermijn bestuur | 6.3yrs |
Recente managementupdates
Recent updates
We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely
Jan 12
Destiny Pharma (LON:DEST) Is In A Good Position To Deliver On Growth Plans
Sep 26We Think Destiny Pharma (LON:DEST) Needs To Drive Business Growth Carefully
May 26Companies Like Destiny Pharma (LON:DEST) Are In A Position To Invest In Growth
Feb 01Will Destiny Pharma (LON:DEST) Spend Its Cash Wisely?
Aug 05Is Destiny Pharma (LON:DEST) In A Good Position To Invest In Growth?
Apr 16What Type Of Shareholders Make Up Destiny Pharma plc's (LON:DEST) Share Registry?
Feb 11
We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely
Nov 30Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Dec 31 2023 | UK£123k | UK£110k | -UK£6m |
Compensatie versus markt: Chris's total compensation ($USD158.25K) is below average for companies of similar size in the UK market ($USD361.35K).
Compensatie versus inkomsten: Insufficient data to compare Chris's compensation with company performance.
CEO
Chris Tovey (59 yo)
less than a year
Tenure
UK£123,000
Compensatie
Mr. Christopher John Tovey, also known as Chris, BSc, serves as Chief Executive Officer & Director of Destiny Pharma plc since September 1, 2023. He had been the Chief Operating Officer at GW Pharmaceutica...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | less than a year | UK£123.00k | 0.042% £ 1.9k | |
| Founder | 27.6yrs | UK£250.00k | 6.8% £ 309.2k | |
| CFO, Company Secretary & Director | 5.8yrs | UK£270.00k | 0.025% £ 1.2k | |
| Interim CMO & Senior Independent Director | less than a year | UK£213.00k | 0.092% £ 4.2k |
3.4yrs
Gemiddelde duur
60.5yo
Gemiddelde leeftijd
Ervaren management: DEST's management team is considered experienced (3.4 years average tenure).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | less than a year | UK£123.00k | 0.042% £ 1.9k | |
| Founder | no data | UK£250.00k | 6.8% £ 309.2k | |
| CFO, Company Secretary & Director | 5.8yrs | UK£270.00k | 0.025% £ 1.2k | |
| Interim CMO & Senior Independent Director | 4.6yrs | UK£213.00k | 0.092% £ 4.2k | |
| Independent Chairman | 8yrs | UK£34.00k | 3.93% £ 178.7k | |
| Member of Scientific Advisory Board | 6.3yrs | geen gegevens | geen gegevens | |
| Non-Executive Director | 2.2yrs | UK£41.00k | 0.36% £ 16.6k | |
| Member of Scientific Advisory Board | 6.3yrs | geen gegevens | geen gegevens | |
| Chair of the Scientific Advisory Board | 6.3yrs | UK£10.66k | geen gegevens | |
| Member of Scientific Advisory Board | 6.3yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 6.3yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens |
6.3yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren bestuur: DEST's board of directors are considered experienced (6.3 years average tenure).